UNSPSC 51171837: Flumeridone

This classification denotes an antiemetic agent with the molecular formula C22H23ClFN5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZZN46QU1N, chemically known as 2h-benzimidazol-2-one, 1-(3-(4-(5-chloro-2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)-1-piperidinyl)propyl)-5-fluoro-1,3-dihydro- but generally known as flumeridone, which bears US NIH Compound Identifier 71758. European Medicines Agency schedules Flumeridone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07697MIG.

UNSPSC 51171837 Flumeridone is a Commodity code under which state and local governments procure pharmaceutical products, specifically generic multi-source drugs and over-the-counter medications distributed through authorized wholesalers and pharmacy benefit programs. The code encompasses both direct pharmaceutical supply contracts and specialized testing services that may incorporate pharmaceutical screening methodologies. State and local issuing bodies soliciting under this code include county community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances representing multiple participating jurisdictions. The scope of recent activity spans generic pharmaceuticals with specific National Drug Codes (NDCs) supplied through established wholesaler networks, offender drug testing services incorporating pharmaceutical screening via immunoassay and confirmatory analysis, and emerging direct-to-manufacturer prescription models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity concentrates in Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department released RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and estimated contract value of $600,000 over two years plus optional renewals; the scope includes staffing two collection sites, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies (oral fluid and hair testing) for approximately 25,031 annual tests. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products sourced through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather preliminary market intelligence on direct-to-manufacturer prescription programs and vendor capabilities in direct contracting with self-insured employers and state agencies, signaling early-stage procurement planning with no formal solicitation timeline or award value disclosed.